<DOC>
	<DOCNO>NCT00258271</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cladribine cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Giving cladribine cytarabine together imatinib mesylate may kill cancer cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together cladribine cytarabine treat patient refractory relapse acute myeloid leukemia blastic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Cladribine , Cytarabine , Imatinib Mesylate Treating Patients With Refractory Relapsed Acute Myeloid Leukemia Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety feasibility cladribine , cytarabine , imatinib mesylate patient refractory relapse acute myeloid leukemia blastic phase chronic myelogenous leukemia . - Determine maximum tolerate dose imatinib mesylate patient treat regimen . - Correlate expression c-kit presence c-kit mutation clinical response patient treat regimen . - Correlate vitro inhibitory effect imatinib mesylate cytarabine proliferation survival leukemic cell clinical response patient treat regimen . OUTLINE : This dose-escalation study imatinib mesylate . Patients receive oral imatinib mesylate daily day 1-15 cladribine IV 2 hour cytarabine IV 4 hour day 3-7 . Patients also receive filgrastim ( G-CSF ) subcutaneously day 2-7 . Treatment repeat every 15 day 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 12-18 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) blastic phase chronic myelogenous leukemia ( CML ) Refractory AML define follow : Failure achieve complete response ( CR ) 2 course induction chemotherapy Persistent bone marrow blast &gt; 40 % 1 course induction chemotherapy Relapse disease within 3 month since CR Relapsed AML define follow : Any evidence disease recurrence CR ( early relapse occur within 312 month late relapse occur &gt; 12 month later ) No acute promyelocytic leukemia ( AMLM3 FAB subgroup ) PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 2.0 mg/dL AST ≤ 2.5 time upper limit normal No known chronic liver disease ( e.g. , chronic active hepatitis cirrhosis ) Renal Creatinine &lt; 2.5 mg/dL ( 2.02.5 mg/dL , glomerular filtration rate must measure dose cytarabine adjust necessary ) Cardiovascular No New York Heart Association grade IIIIV heart disease No congestive heart failure No myocardial infarction within past 6 month Ejection fraction ≥ 30 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment No uncontrolled systemic active infection No known HIV infection No history allergic reaction attribute compound similar chemical biological composition study drug No history curatively treat malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic agent Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent birth control pills Other More 1 week since prior investigational agent No concurrent investigational agent therapies No concurrent anticancer agents No concurrent therapeutic anticoagulation warfarin Low molecular weight heparin heparin allow therapeutic anticoagulation Minidose warfarin ( e.g. , 1 mg per day ) allow prophylaxis central venous catheter thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>